微粒化非诺贝特治疗糖尿病血脂异常及其对血清C-反应蛋白的影响

目的:观察微粒化非诺贝特治疗糖尿病(DM)血脂异常及其对血清C-反应蛋白(C-RP)的影响。方法:选择1999年1月~2004年12月门诊及住院的2型糖尿病(T2DM)患者共86例,将上述患者随机分成治疗组44例,对照组42例。治疗组给予微粒化非诺贝特200 mg,每晚服用,连续8周;对照组给予辛伐他汀10 mg,每晚服用,连续8周。分别于治疗前和治疗后8周检查血脂常规、C-RP、肝功能、血常规、血糖等指标。结果:治疗组与对照组治疗8周后,血清甘油三脂(TG)明显降低(P<0.01)、高密度脂蛋白胆固醇(HDL-C)显著增加(P<0.01),两组比较有显著差异(P<0.01);两组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、C-RP均有显著下降(P<0.01),但两组比较无显著差异(P>0.05)。结论:微粒化非诺贝特治疗糖尿病血脂异常有确切调脂及抗炎作用。

Effect of micronised fenofibrate on the treatment of diabetes mellitus dyslipidemia and on the C-reactive protein

Objective:To observe the effects of micronised fenofibrate on the treatment of diabetes mellitus(DM) dyslipidemia and on the C-reactive protein.Methods:During 1999-01～2004-12,86 patients with T2DM were randomly divided into two groups:The treatment group(n=44) and the control group(n=42).The treated group was given 200 microgram of micronised fenofibrate every night for 8 weeks.The control group was given 10 microgram of simvastatin every night for 8 weeks.Compare the TG,TC,HDL-C,LDL-C and C-RP before treatment and 8 weeks later respectively.Results:Compared with the control group after 8 weeks treatment,the TG decreased significantly(P<0.01).The HDL-C increased significantly(P<0.01),and there is significantly different between two groups(P<0.01).The TC,LDL-C and C-RP had been decreased significantly(P<0.01),but were no significantly different between two groups(P>0.05).Coclusion:The patients with DM dyslipidemia can be improved by micronised fenofibrate.